Solid Biosciences Inc. (SLDB)
NASDAQ: SLDB · Real-Time Price · USD
6.31
+0.13 (2.10%)
At close: Feb 25, 2026, 4:00 PM EST
6.30
-0.01 (-0.16%)
Pre-market: Feb 26, 2026, 7:25 AM EST
Solid Biosciences Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
100
Market Cap
491.61M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | 8.09M | -5.53M | -40.57% |
| Dec 31, 2021 | 13.62M | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Keros Therapeutics | 246.72M |
| Vanda Pharmaceuticals | 216.11M |
| Autolus Therapeutics | 51.13M |
| Invivyd | 50.04M |
| Assembly Biosciences | 37.19M |
| Prothena Corporation | 9.68M |
| Lyell Immunopharma | 41.00K |
| vTv Therapeutics | 17.00K |
SLDB News
- 12 days ago - Solid Biosciences Inc. (SLDB) Presents at Guggenheim Securities Emerging Outlook: Biotech Summit 2026 Transcript - Seeking Alpha
- 16 days ago - Solid Biosciences: Positive FDA Meeting For SGT-003 Sets Up Next Milestones - Seeking Alpha
- 17 days ago - Solid Biosciences Announces Positive Feedback from Type C Meeting with FDA for SGT-003 Gene Therapy for Duchenne Muscular Dystrophy - GlobeNewsWire
- 20 days ago - Solid Biosciences to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026 - GlobeNewsWire
- 6 weeks ago - Solid Biosciences Inc. (SLDB) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha
- 6 weeks ago - Solid Biosciences Provides 2026 Outlook Underscoring Neuromuscular and Cardiac Pipeline Momentum and Expanded Access to Next-Generation Capsid AAV-SLB101 - GlobeNewsWire
- 6 weeks ago - Solid Biosciences Receives FDA Orphan Drug Designation for SGT-212 Dual-Route Gene Therapy for the Treatment of Friedreich's Ataxia - GlobeNewsWire
- 6 weeks ago - Solid Biosciences Doses First Participant in First-in-Class Phase 1b FALCON Trial Evaluating SGT-212 Dual-Route Gene Therapy for the Treatment of Friedreich's Ataxia - GlobeNewsWire